Welcome to the official InxMed website




Ifebemtinib (also known as IN10018, ifebe, BI853520) is  an orally administered, highly potent and selective small molecular inhibitor of the focal adhesion kinase (FAK). InxMed translational research has advanced FAK targeting as an essential mean to fight against cancer.  


Anchor Targeting Tumor Defense with POC achieved over different indications

Ifebemtinib has a significant synergy with a broad spectrum of therapeutic modalities. Clinically, ifebemtinib has demonstrated therapeutic synergy with chemotherapy agents, targeted therapies, antibody-drug conjugates, and immunotherapies. InxMed is currently pursuing a registrational trial in platinum-resistant ovarian cancer in China, and multiple proof-of-concept trials are ongoing in lung, colorectal, melanoma, and pancreatic cancers, with selected tumor types to progress into pivotal clinical trials. 

 Good Safety Profile

Good Safety Profile

Ifebemtinib demonstrated good safety profile demonstrated in more than 600 patients. Single agent or in combination with PLD, docetaxel, paclitaxel-carboplatin, cobimetinib, and anti-PD(L)-1 in multiple solid tumors. Most common AEs include reversible proteinuria, Gl related side effects. The majority of ifebemtinib-related AEs are CTCAE grade 1 or 2. Safety profile for combo is consistent to AE profile of single agent, nooverlapping toxicity reported.



Registrational Stage with Breakthrough Potential

Ifebemtinib received fast track designation from the U.S. Food and Drug Administration (FDA) in August 2021, and breakthrough designation from China National Medical Products Administration (NMPA) in April 2022. A placebo-controlled, randomized, double-blind pivotal trial is ongoing in platinum-resistant ovarian cancer (PROC). The company plans to submit a New Drug Application to the NMPA in early 2025. 

Ifebemtinib would have the biggest impacts via synergy with two unprecedent opportunities for cancer treatment: RASi and ADC, potentially powering toward IO therapyFurther expansions of ifebemtinib to pivotal trials in combination with RAS inhibitors and POC trials in combination with ADC are already in preparation. 


Registrational Stage

We invent personalized medicines with global impact, and turn innovation in China to life saving therapies for the world



Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing


Follow Us:

CopyRight © 2022 InxMed All Rights Reserved.

Powered by: 300.cn | SEO